Selective Androgen Receptor Modulators (SARMs) in the World of Sports

Onur Oral¹, George Nomikos² and Nikitas Nomikos^{3, 4,}

¹Department of Health Sciences and Sports, Ege University Faculty of Sport Sciences, Izmir, Turkey

²Department of Orthopaedic Surgery, Chios Hospital, Chios, Greece

³School of Physical Education & Sport Science, National & Kapodistrian University of Athens

⁴Medical School, National & Kapodistrian University of Athens, Greece

Cite this paper:
Onur Oral, George Nomikos and Nikitas Nomikos. Selective Androgen Receptor Modulators (SARMs) in the World of Sports. American Journal of Medical Sciences and Medicine. 2020; 8(4):153-156. doi: 10.12691/ajmsm-8-4-3

Abstract

Background: The study aims to investigate the effects of selective androgen receptor modulators (SARMs) among athletes and examine the possible beneficial results and risks of these substances for the athletes' health and performance and human health in general. Nowadays, SARMs have become a focus of interest in the world of sports and medicine. Because of their anabolic action, SARMs are considered quite promising for treating several disorders including breast cancer, osteoporosis, DMD (Duchenne Muscular Dystrophy), some type of tumors, etc. As for the athletic community, SARMs are used as doping for muscle mass increasing and strengthening and pose as an alternative to other steroid-based doping with their minimum side effects. SARMs are innovative substances for athletic performance and human health. Further study on SARMs is required in order to understand the long-term effects on human health and athletic performance.

Keywords:
SARMs anabolic action testosterone doping

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Clark R.V., Walker A.C., Andrews S., Turnbull P., Wald J.A., Magee M.H., Safety, pharmacokinetics, and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women, Br J Clin Pharmacol, 2017, 83(10): 2179-2194.
[2]	Saitoh M., Ebner N., von Haehling S., Anker S.D., Springer J., Therapeutic considerations of sarcopenia in heart failure patients, Expert Rev Cardiovasc Ther., 2018, 16(2): 133-142
[3]	Srinath R., Dobs A., Enobosarm (GTx-024, S-22): a potential treatment for cachexia, Future Oncol., 2014, 10(2): 187-194.
[4]	Coss C.C., Jones A., Hancock M.L., Steiner M.S., Dalton J.T., Selective androgen receptor modulators for the treatment of late-onset male hypogonadism, Asian J Androl., 2014, 16: 256-261.
[5]	Megumi M., Katsuji A., Takahito H., Masuo Y., Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models, Oncol Lett., 2017, 14: 8066-8071.
[6]	Narayanan R., Ahn S., Cheney M.D., Yepuru M., Miller D.D., Steiner M.S., Dalton J.T., Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial: mesenchymal stem cell signaling, Plos One, 2014, 9(7): 103-202. 27.
[7]	Narayanan R., Coss C.C., Dalton J.T., Development of selective androgen receptor modulators (SARMs), Mol Cell Endocrinol., 2108, 465: 134-142.
[8]	Narayanan R., Dalton J.T., Androgen receptor: A complex therapeutic target for breast cancers, Cancers (Basel), 2016, 8(12): 1-17.
[9]	Miklos A., Tero-Vescan A., Vari C.E., et al., Selective Androgen Receptor Modulators (SARMs) In The Context Of Doping, Farmacia, 2018, 66 (5), 758-762.
[10]	Krishnan V., Patel N.J., Mackrell J.G., et al., Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. Andrology, 2018, 6(3): 455-464.
[11]	Pantea-Stoian A., Pițuru S.M., Hainăroșie R., Testosterone therapy, new opportunities in diabetes mellitus, Farmacia, 2018, 66(1): 1-7.
[12]	World Anti-Doping Agency. The 2018 Prohibited List, 2018, www.wada-ama.org.
[13]	World Anti-Doping Agency. World Anti-Doping Code, 2018. www.wada-ama.org.
[14]	Rahnema C.D., Lipshultz L.I., Crosnoe L.E., et al,. Anabolic steroid–induced hypogonadism: diagnosis and treatment, Fertil Steril., 2014, 101(5): 1271-1279.
[15]	Wagels L., Votinov M., Kellermann T., et al., Exogenous Testosterone Enhances the Reactivity to Social Provocation in Males, Front BehavNeurosci., 2018, 12: 1-11.
[16]	Goldman A., Basaria S., Adverse health effects of androgen use, Moll Cell Endocrinol., 2018, 15; 464: 46-55.
[17]	Jayaraman A., Christensen A., Moser V.A., et al., Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats, Endocrinol., 2014, 155: 1398-1406.
[18]	Chen J., Kim J., Dalton J.T., Discovery and therapeutic promise of selective androgen receptor modulators, Mol Interv., 2005, 5(3): 173-188.
[19]	Gao W, Reiser P.J., Coss C.C., et al., Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats, Endocrinology., 2005, 146: 4887-4897.
[20]	Hanada K., Furuya K., Yamamoto N., et al., Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis, Biol Pharm Bull., 2013, 26: 1563-1569.
[21]	Mohler M.L., Nair V.A., Hwang D.J., et al., Nonsteroidal Tissue Selective Androgen Receptor Modulators: A Promising Class of Clinical Candidates, Expert Opinion in Therapeutic Patents., 2005, 15(11): 1565-1585.
[22]	Kearbey J.D., Gao W., Narayanan R., et al., Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats, Pharm Res., 2007, 24: 328-335.
[23]	Carmeli E., Coleman R., Reznick A.Z., The biochemistry of aging muscle, Exp Gerontol., 2002, 37: 477-489.
[24]	Bosy-Westphal A., Eichhorn C., Kutzner D., et al., The age-related decline in resting energy expenditure in humans is due to the loss of fat-free mass and to alterations in its metabolically active components, J Nutr., 2003, 133: 2356-2362.
[25]	Dobs A.S., Boccia R.V., Croot C.C., et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial, Lancet Oncol., 2013, 14:335-345. Eur J Pharmacol, 720, pp. 107-114.
[26]	Dalton J.T., Barnette K.G., Bohl C.E., et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial, J Cachexia Sarcopenia Muscle., 2011, 2: 153-161.
[27]	Rahimov F., Kunkel L.M., The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy, J Cell Biol., 2013, 201: 499-510.
[28]	Frankel K.A., Rosser R.J., The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol., 1976, 7:375-386.
[29]	Politano L., Nigro V., Nigro G., et al., Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies, JAMA., 1996, 275: 1335-1338. Prostate, 72, pp. 1580-1587.
[30]	Simon J.A., Goldstein I., Kim N.N., et al., The role of androgens in the treatment of genitourinary syndrome of menopause (GSM), International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause, 2018, 25 pp. 837-847
[31]	Vignozzi L., Corona G., Petrone L., et al., Testosterone and sexual activity, J EndocrinolInvest, 2005, 28 pp. 39-44.
[32]	Solomon Z.J., Mirabal J.R., Mazur D.J., et al., Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications, Sex Med Rev, 2018, 7(1): 84-94.
[33]	Jones A., Hwang D.J., Duke C.B., et al., Nonsteroidal selective androgen receptor modulators enhance female sexual motivation, 2010.
[34]	Akita K., Harada K., Ichihara J., et al., A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate, 2013.
[35]	Thevis M., Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product, Drug Test Anal, 2009, 1, pp. 387-392
[36]	Mason R.A., Morris H.A., Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats, J Bone Miner Res., 1997, 12: 1431-1437.
[37]	Cozzoli A., Capogrosso R.F., Sblendorio V.T., GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy, Pharmacol Res., 2013, 72: 9-24.
[38]	Basaria S., Collins L., Dillon E.L., et al., The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men, J Gerontol A Biol Sci Med Sci., 2013, 68(1): 87-95.
[39]	Papanicolaou D.A., Ather S.N., Zhu H., et al., A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia, J Nutr Health Aging, 2013, 17(6): 533-43.
[40]	Nejishima H., Yamamoto N., Suzuki M., et al., Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia, 2012.